INCHEON, Corée–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. a annoncé aujourd’hui avoir commencé la commercialisation directe de BYOOVIZ®, un médicament biosimilaire du Lucentis1 (ranibizumab), en Europe. Samsung Bioepis s’est efforcé d’assurer un trans…
Category: News
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously a…
US FDA Declines to Approve Outlook’s Eye Disease Drug for Second Time in 2025
Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, dealing another blow in the company’s prolonged… Reuters Health Information
17-Year-Old Young Tissue Recipient and 14 Tissue Donors to Share the Healing Power of Cornea and Tissue Donation at the 2026 OneLegacy Donate Life Rose Parade® Float
AZUSA, Calif.–(BUSINESS WIRE)–A 17-year-old high school junior from Pomeroy, WA and 14 cornea and tissue donors will be honored on the 2026 OneLegacy Donate Life float, Treasure Every Moment Together, as part of the iconic Rose Parade® on New Year’s …
No Complications With First Human Robotic Cataract Surgery
A small proof-of-concept study of robotic-assisted cataract surgery reports successful outcomes with no treatment-related adverse events. Medscape Medical News
L'FDA approva le prime lenti a contatto con profondità di focalizzazione estesa per la presbiopia
BOCA RATON, Fla.–(BUSINESS WIRE)–The Cataltheia Group e la sua controllata, Bruno Vision Care LLC, azienda leader nell’innovazione della salute degli occhi, oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha approvato la pri…
La FDA autorise la première lentille de contact à profondeur de champ étendue pour la presbytie
BOCA RATON, Floride–(BUSINESS WIRE)–Cataltheia Group et sa filiale américaine Bruno Vision Care LLC, leader dans le domaine de l’innovation en matière de santé oculaire, ont annoncé aujourd’hui que la Food and Drug Administration (FDA) américaine ava…
La FDA autoriza la primera lente de contacto con profundidad de foco extendida para la presbicia
BOCA RATÓN, Florida–(BUSINESS WIRE)–Cataltheia Group y su filial en los Estados Unidos, Bruno Vision Care LLC, líder en innovación en salud ocular, anunciaron hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha autori…
FDA keurt eerste Extended Depth of Focus-contactlens voor presbyopie goed
BOCA RATON, Fla.–(BUSINESS WIRE)–De Cataltheia Group en Bruno Vision Care LLC, de Amerikaanse dochteronderneming van het bedrijf en leider op gebied van innovatie voor de gezondheid van de ogen, maakten vandaag bekend dat de Amerikaanse FDA (U.S. Foo…
FDA genehmigt erste Kontaktlinse mit erweiterter Tiefenschärfe für Presbyopie
BOCA RATON, Fla.–(BUSINESS WIRE)–Die Cataltheia Group und ihre US-Tochtergesellschaft Bruno Vision Care LLC, ein führendes Unternehmen im Bereich der Augenheilkunde, gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Dru…
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia
BOCA RATON, Fla.–(BUSINESS WIRE)–The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable …
The 12 Dangers of Christmas
Echoing the 12 Days of Christmas, this festive guide outlines the seasonal risks clinicians can help patients avoid. Medscape News UK
Aflibercept 8 mg Promising Alternative to 2 mg for PCV
Aflibercept 8 mg provides similar outcomes for vision and eye structure as the 2-mg dose in patients with polypoidal choroidal vasculopathy, a recent study finds. Medscape Medical News
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth po…
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR t…
Ollin Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced that Jason Ehrlich, M.D., Ph.D….
Bausch + Lomb Announces Two Board of Directors Appointments
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appoin…
Future Forward Labs Appoints Dr. Delia DeBuc as Applied Science Mentor to Advance Applied Physics and Biomedical Innovation
SEATTLE–(BUSINESS WIRE)– #highschool–Future Forward Labs today announced the appointment of Dr. Delia DeBuc as STEM Mentor – Applied Physics and Biomedical Science. Dr. DeBuc brings more than 20 years of multidisciplinary research, scientific leader…
Dompé verabreicht Isocyclosporin an erste Patienten einer Phase-3-Studie in Europa und den USA für die Indikation atopische Keratokonjunktivitis
MAILAND und SAN MATEO, Kalifornien, USA–(BUSINESS WIRE)–Dompé, ein führendes Biopharmaunternehmen mit Niederlassungen in Italien und den USA, meldete die Aufnahme der ersten Patienten in eine Phase-3-Studie zu Isocyclosporin für die Behandlung von at…